Name: Anti-Human CD38 (Isatuximab Biosimilar)
Brand: InnoCyto
SKU: 503503
Price: 2000 USD
Availability: InStock

Shop Now Contact

Anti-Human CD38 (Isatuximab Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
503501	1 mg	$250
503502	5 mg	$650
503503	20 mg	$2000

Bulk/Custom

Product Details

Clone	Isatuximab
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Reactivity	Human
Format	Liquid
Product Description	Isatuximab Biosimilar, CD38 Monoclonal Antibody
Isotype	Human IgG1
Regulatory Status	RUO
Clonality	Recombinant
Immunogen	Human CD38
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Min Sample Size	1 mg
Storage Conditions	4ºC
Maximal Shelf Life	12 months
Target Name	CD38, gp45, Cyclic ADP-ribose hydrolase 1,T10, ADP-ribosyl cyclase
Antibody Type	Recombinant
Research Areas	Cancer Marker, T cells, B cells, NK cells, Monocytes, Macrophages, Plasma cells
See All Formats	Clone Isatuximab

Background Information

Isatuximab is a chimeric monoclonal antibody of the immunoglobulin G1 kappa (IgG1κ) subclass designed to specifically target CD38, a multifunctional transmembrane glycoprotein expressed on various immune and hematopoietic cell types. Structurally, Isatuximab is a glycoprotein with a molecular weight of approximately 150 kilodaltons (kDa). It is composed of two identical heavy chains and two identical light chains joined by interchain disulfide bonds, forming the canonical Y-shaped structure characteristic of IgG antibodies. Each heavy chain contains a variable (VH) domain and three constant domains (CH1-CH3), and each light chain contains a variable (VL) and a constant (CL) domain. The molecule is produced using mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, which ensure proper folding, assembly, and glycosylation consistent with human immunoglobulins.

The antigen-binding sites of Isatuximab are formed by complementarity-determining regions (CDRs) within the VH and VL domains. These CDRs determine the antibody’s epitope specificity for CD38, binding with high affinity through a network of hydrogen bonds and hydrophobic interactions. The recognized epitope on CD38 lies within its extracellular catalytic domain, which functions as an ectoenzyme involved in the metabolism of nicotinamide adenine dinucleotide (NAD⁺) and cyclic ADP-ribose. By binding to CD38, Isatuximab interferes with its enzymatic activity and can induce receptor clustering that modulates signaling pathways, influencing calcium flux and cell activation in immunological models. Furthermore, engagement of CD38 may promote direct cell death mechanisms through apoptotic or lysosomal pathways under defined experimental conditions.

The Fc (fragment crystallizable) region of Isatuximab, derived from the IgG1 isotype, contributes to molecular stability and prolongs serum half-life via neonatal Fc receptor (FcRn) recycling. It can also engage Fc gamma receptors (FcγRs) and complement component C1q, mediating antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in vitro.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips